Alessandro Manenti | Chief Development Officer
VisMederi S.r.l.

Dr. Alessandro Manenti graduated in Biology obtaining his Bachelor’s Degree in 2009 and a Master’s Degree in Molecular Evolution in 2013 at the University of Siena. He worked for six months in a big company in the field of Life Sciences (Novartis). In November 2013, he won a competition for PhD students in Biochemistry and Molecular Biology at the University of Siena. In the first year, he worked on a project of Influenza viral growth in cell culture. In the summer 2015, he spent five months at the Influenza Centre in Bergen, Norway, under the direction of Professor Rebecca Jane Cox, studying the field of validation of new serological assays for IgA and IgG detection. In 2016 he joined VisMederi as Project Leader in the Research department coordinating a group of researchers involved in the development and standardization of new serological assays. He developed in VisMederi the ELLA test for anti-NA antibodies by means of the Triton-X treatment of wild-type influenza viruses and pseudo-viruses, several assays for the detection and quantitation of anti-HA IgA antibodies in nasal and saliva samples, anti HA2-stem IgG antibodies for the assessment of Universal Influenza vaccines. During the SARS-CoV-2 outbreak in 2020, he developed and published the first neutralization assay by means of the authentic strain working in VisMederi BSL3 facilities. In 2021 he joined the position of Chief Development Officer in VisMederi. Dr. Alessandro Manenti is currently the responsible for the business development in VisMederi as well as is responsible of the R&D department.